IV 期弥漫性大 B 细胞淋巴瘤的长期自发性消退。

Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma.

机构信息

Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.

Division of Stem Cell Therapy, Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

出版信息

J Clin Exp Hematop. 2021 Sep 10;61(3):168-172. doi: 10.3960/jslrt.21002. Epub 2021 Jun 30.

DOI:10.3960/jslrt.21002

PMID:34193754

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8519247/

Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive disorder accounting for >30% of all lymphomas. Its prognosis is poor due to a high relapse rate. Spontaneous regression (SR) in DLBCL is rare, with only a few reported cases. Moreover, almost all of these were low-grade lymphomas with an average SR duration of 13 mo. As the cause of SR is unknown, there are many theories such as trauma, infection, medication, and an antitumor immune response. We present a patient with progressive DLBCL who demonstrated SR for >42 mo. Although treatment for lymphoma usually starts soon after diagnosis, insights into SR of lymphomas may lead to new treatment strategies.

摘要

弥漫性大 B 细胞淋巴瘤（DLBCL）是一种侵袭性疾病，占所有淋巴瘤的>30%。由于复发率高，其预后较差。DLBCL 的自发消退（SR）非常罕见，仅有少数报道病例。此外，这些病例几乎都是低级别的淋巴瘤，SR 平均持续时间为 13 个月。由于 SR 的原因尚不清楚，因此有许多理论，如创伤、感染、药物和抗肿瘤免疫反应。我们报告了一例进行性 DLBCL 患者，其 SR 持续时间>42 个月。尽管淋巴瘤的治疗通常在诊断后不久开始，但对淋巴瘤 SR 的深入了解可能会带来新的治疗策略。